Skip to main content

Clinical trial IPAX-1

A multi-centre, open-label, single-arm, dose-finding phase I/II study to evaluate safety, tolerability, dosing schedule, and preliminary efficacy of carrier-added 4-L-[131I]iodo-phenylalanine (131I-IPA), administered as single or repetitive injections in patients with recurrent glioblastoma multiforme (GBM), concomitantly to 2nd line external radiation therapy (XRT) - IPAX-1

Cancers
Organ Liver
Trial status Trial open for recruitment
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 1/2
Academic trial Non
Sponsor Telix International Pty Ltd
EudraCT Identifier 2018-002262-39
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03849105
Inclusion criteria *Previously confirmed histological diagnosis of glioblastoma, with current clinical or imaging evidence for recurrence *Interval since end of 1st line XRT superior or equal to 6 months*Amino acid-based molecular imaging indicating pathologically increase
Last update